biostudies-literatureUnknown40(7)Gonzalez-Robles CEdmond J. Safra Philanthropic Foundation<h4>Background</h4>There are currently no disease-modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative will expedite clinical assessment of putative DMTs through a multi-arm multistage (MAMS) trial, testing several treatments against a common placebo arm and replacing unsuccessful therapies early.<h4>Objective</h4>The objective of this study was to describe the treatment selection process for the EJS ACT-PD clinical trial platform.<h4>Methods</h4>A Treatment Selection Working Group (TSWG) identified compounds using complementary strategies, such as literature search, related initiatives (Cure Parkinson's International Linked Clinical Trials [iLCT] initiative), and expert suggestionsMovement disorders : official journal of the Movement Disorder Society1307-1317https://www.ebi.ac.uk/biostudies/studies/S-EPMC12273612biostudies-literatureTreatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.PMC12273612Bandmann OAllison JMullin SDexter DTClarke CSJabbari EHockey KKhengar RBale CPetty RBakshi NMartin KMortiboys HMcFarthing KBarber TRDuty SGreaves VCroucher RKapur NFletcher KMatthews KMatthews HStott SEdwards MCarroll CBWonnacott SGandhi SForbes JJewell AHenderson EGros PScurfield PWyse RKRatcliffe NTofaris GKBartlett MMiller LParry Mvan Wamelen DKorlipara PEdwards ADeeson EHu MTWong AAthauda DWei LHandley JBlack JJha AWilliams-Gray CHBhatia KEJS ACT‐PD ConsortiumAgarwal VMillo SHHudson FDrew CBarker RAYarnall ANavangul AChaudhuri KRBartolomeu-Pires SBurnell MLambert CZetterberg HGonzalez-Robles CCarpenter JMills GBarker RDexter DBarber TSammler EFoltynie TWeil RSBreen DDuffen JEllis-Doyle RSilverdale MWhone AStott SRWSchrag AHuxford BTofaris GBatla ALawton MPiccini PPushparatnam KSchapira AHMorris HNoyce ACounsell CSiu CCollins SSchapira AHVZeissler MLRochester LBen-Shlomo YAli SCollins HfalseTreatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.<h4>Background</h4>There are currently no disease-modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative will expedite clinical assessment of putative DMTs through a multi-arm multistage (MAMS) trial, testing several treatments against a common placebo arm and replacing unsuccessful therapies early.<h4>Objective</h4>The objective of this study was to describe the treatment selection process for the EJS ACT-PD clinical trial platform.<h4>Methods</h4>A Treatment Selection Working Group (TSWG) identified compounds using complementary strategies, such as literature search, related initiatives (Cure Parkinson's International Linked Clinical Trials [iLCT] initiative), and expert suggestions2025-01-01T00:00:00Z2025 Jul2025-08-31T03:11:21.802Z2025-08-31T03:05:14.714ZS-EPMC122736124024927510.1002/mds.30190